- Home
- YJ vs CVKD Comparison
YJ vs CVKD Comparison
Compare YJ & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YJ | CVKD |
|---|---|---|
| Founded | 2015 | 2022 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | YJ | CVKD |
|---|---|---|
| Price | $1.50 | $4.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 4.7K | ★ 42.6K |
| Earning Date | 03-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $4.21 |
| 52 Week High | $2.67 | $17.50 |
Technical Indicators
Market Signals| Indicator | YJ | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 31.57 |
| Support Level | $1.38 | N/A |
| Resistance Level | $1.72 | $14.21 |
| Average True Range (ATR) | 0.13 | 0.67 |
| MACD | -0.05 | -0.20 |
| Stochastic Oscillator | 4.55 | 7.94 |
Price Performance
Historical ComparisonAbout YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.